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Background
Coxsackievirus A21 (CVA21) is a naturally occurring
“common cold” intercellular adhesion molecule-1
(ICAM-1)-targeted RNA virus. Surface ICAM-1 is up-
regulated on a number of cancers including melanoma,
non-small cell lung, bladder and prostate cancers.
CAVATAK is a novel bio-selected formulation of
CVA21, which displays potent oncolytic activity against
in vitro cultures of cancer cells and in vivo xenografts of
a number of cancers. In this Phase I/II study advanced
cancer patients received multiple intravenous (IV) doses
of CAVATAK to assess treatment tolerance, levels of
viral replication and viral-induced immune activation
within the tumor micro-environment.
Methods
The Phase I/II STORM (Systemic Treatment Of Resis-
tant Malignancies: NCT02043665) study is investigating
the tolerance of multiple escalating IV doses of CVA21
in approximately 30 advanced cancer patients. In cohort
1 (n=3), patients were infused with CVA21 at a dose of
1 × 108 TCID50, in cohort 2 (n=3), patients were infused
with CVA21 at a dose of 3 × 108 TCID50 and treatment
of patients in Cohort 3 (n=12-18) with CVA21 at a dose
of 1 × 109 TCID50 has commenced. Tumor biopsies at
8 days following the initial CVA21 infusion are being
monitored for levels of virus and markers of potential
immune activation. Sequential serum samples are being
analyzed for viral loads, kinetics of anti-CVA21 neutra-
lizing antibody (nAb) development and immune system
activation via relative serum levels of a panel of immune
cytokines/cell subsets.
Results
To date multi-dose intravenous administration to patients
in Cohorts 1,2 and 3 has been well tolerated, with no Grade
3 or 4 product-related AE's. Preliminary data indicate that
the prolonged presence of serum CVA21 RNA in some, but
not all, patients at times (up to 4 days post-infusion), when
complete decay of the administered viral dose was expected
may indicate possible viral replication within the tumor . Evi-
dence of CVA21 tumor targeting is confirmed with 2 of
2 melanoma patients in Cohort 3 displaying replicating
CVA21 in tumor biopsies. Such replication in pre-clinical
melanoma xenograft models was potentially immunogenic,
as evidenced by gene expression increases of CXCL-10 and
PD-L1. The interim dataalso highlight a robust “multi-
dosing-window” in the absence of significant levels of
nAb for approximately 7 days post initial viral infusion.
Conclusions
Preliminary data offer an exciting possibly that tumor
targeting, infection and immune activation mediated by
IV CVA21 may lead to increases in anti-tumor activity,
particularly when in future used in combination with
immune checkpoint blockade.
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